GW Pharmaceuticals PLCGWP:LSE

241.25
4.50 / 1.83%
164.43k
41.30 %
1.07
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Feb 09 2016 09:33 GMT.
GWP:LSE is traded on the London Stock Exchange Alternative Investment Market (Aim)

Consensus recommendation

As of Feb 06, 2016, the consensus forecast amongst 2 polled investment analysts covering GW Pharmaceuticals plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jan 13, 2016. The previous consensus forecast advised investors to purchase equity in GW Pharmaceuticals plc.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy1
Outperform0
Hold1
Underperform0
Sell0
No opinion0

Share price forecast

The 2 analysts offering 12 month price targets for GW Pharmaceuticals plc have a median target of 4,578.28, with a high estimate of 8,596.56 and a low estimate of 560.00. The median estimate represents a 1,762.98% increase from the last price of 245.75. View Full Financials

High+3,463.3 %8,596.56
Med+1,797.7 %4,578.28
Low+132.1 %560.00

Dividends

Dividend information is not available for GW Pharmaceuticals PLC. View Full Financials

Earnings history & estimates

On Dec 07, 2015, GW Pharmaceuticals plc reported 4th quarter 2015 losses of -0.047 per share. This result under-performed the breakeven expectation of the 3 analysts following the company but under-performed last year's 4th quarter results by -0.048.
The next earnings announcement is expected on Feb 10, 2016. View Full Interim Financials

Average growth rate-83.16 %

GW Pharmaceuticals plc reported annual 2015 losses of -0.181 per share on Dec 07, 2015. View Full Annual Financials

Average growth rate-100.63 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

GW Pharmaceuticals plc had 4th quarter 2015 revenues of 5.60m. This missed the 18.33m consensus estimate of the 3 analysts following the company. The same period last year the company did not report revenues. View Full Interim Financials

Average growth rate-3.68 %

GW Pharmaceuticals plc had revenues for the full year 2015 of 28.54m. This was 5.01 % below the prior year's results. View Full Annual Financials

Average growth rate-0.18 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.